Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brimonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 20/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 19/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 19/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 14/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 11/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 12/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | HTR1A | P08908 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brimonidine SCHEMBL27455839 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29377437 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29470063 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL2400529 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL34647 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29378438 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL34649 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL22616168 | 0.99 | ADRA2A (0.98) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL22616169 | 0.99 | ADRA2A (0.98) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29227701 | 0.99 | ADRA2A (0.98) | ADRA2AADRA2BADRA2CADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 424 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119739968-A | Multi-scale flow state fault diagnosis system for circulating fluidized bed | 中煤陕西能源化工集团有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-119300588-A | Preparation method of full-color display array structure with light isolation | 南京阿吉必信息科技有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-119226920-A | User data isolation and processing analysis method of operating system | 上海商甲信息科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-117782898-B | Testing method of shale gas bidirectional diffusion coefficient measuring device under triaxial stress | 中国地质大学（武汉） | 2024-07-05 | — | — | CN | claimed |
| US-20230390219-A1 | BENZALKONIUM CHLORIDE FORUSE IN TREATING CONJUNCTIVITIS AND/OR COVID-19 | BAUSCH + LOMB IRELAND LIMITED (IE) | 2023-12-07 | — | — | US | claimed |
| EP-4228617-A1 | BENZALKONIUM CHLORIDE FOR USE IN TREATING CONJUNCTIVITIS AND/OR COVID-19 | Bausch + Lomb Ireland Limited (IE) | 2023-08-23 | — | — | EP | claimed |
| CN-114580746-A | Comprehensive energy station composite energy storage configuration optimization method based on low-carbon economic benefit quantification | 无锡机电高等职业技术学校 | 2022-06-03 | — | — | CN | claimed |
| WO-2022079664-A1 | BENZALKONIUM CHLORIDE FOR USE IN TREATING CONJUNCTIVITIS AND/OR COVID-19 | Bausch & Lomb Ireland Limited (IE) | 2022-04-21 | — | — | WO | claimed |
| US-20260137368-A1 | ULTRASOUND NAVIGATION SYSTEM WITH SIMPLIFIED PROBE POSITIONING INSTRUCTIONS | ULTRASIGHT LTD (IL) | 2026-05-21 | — | — | US | disclosed |
| WO-2026105117-A1 | ULTRASOUND NAVIGATION SYSTEM WITH SIMPLIFIED PROBE POSITIONING INSTRUCTIONS | ULTRASIGHT LTD. (IL) | 2026-05-21 | — | — | WO | disclosed |
| EP-4463821-B1 | SYSTEMS, METHODS, AND APPARATUSES FOR PLEURAL LINE DETECTION | KONINKLIJKE PHILIPS NV (NL) | 2026-04-29 | — | — | EP | disclosed |
| US-12611176-B2 | Intraluminal imaging devices with a reduced number of signal channels | PHILIPS IMAGE GUIDED THERAPY CORPORATION (US) | 2026-04-28 | — | — | US | disclosed |
| US-12606868-B2 | Molecular biomarkers and targets for Fuchs' endothelial corneal dystrophy and glaucoma | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4721725-A2 | TREATMENT OF PRESBYOPIA AND MYDRIASIS WITH PHENTOLAMINE | Opus Genetics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-3833489-B1 | INTERVENTIONAL DEVICE WITH PVDF ULTRASOUND DETECTOR | KONINKLIJKE PHILIPS NV (NL) | 2022-03-02 | — | — | EP | disclosed |
| WO-2022039887-A1 | LOW-DOSE OPHTHALMIC COMPOSITIONS AND METHODS | VYLUMA INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-3954362-A1 | METHOD OF INCREASING BIOAVAILABILITY AND/OR PROLONGING OPHTHALMIC ACTION OF A DRUG | Sun Pharma Advanced Research Company Ltd (IN) | 2022-02-16 | — | — | EP | disclosed |
| US-20220040207-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220039772-A1 | SUBLINGUAL MICROCIRCULATION DETECTION DEVICE, SUBLINGUAL MICROCIRCULATION DETECTION SYSTEM AND PROCESSING METHOD THEREOF | ZHEJIANG UNIVERSITY (CN) | 2022-02-10 | — | — | US | disclosed |
| EP-3833264-B1 | INTERVENTIONAL DEVICE WITH AN ULTRASOUND TRANSDUCER | KONINKLIJKE PHILIPS NV (NL) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040207-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | HIF1AN, RHOXF2, HIF1A | ADRA2A 2508/4885ADRA2B 2454/4885ADRA2C 2903/4885 |
| US-12611176-B2 | Intraluminal imaging devices with a reduced number of signal channels | FABP3, TNNI3, MEF2D | ADRA2A 1309/4885ADRA2B 1912/4885ADRA2C 1414/4885 |
| US-20230390219-A1 | BENZALKONIUM CHLORIDE FORUSE IN TREATING CONJUNCTIVITIS AND/OR COVID-19 | ACE, ACHE, ACE2 | ADRA2A 1206/4885ADRA2B 917/4885ADRA2C 1072/4885 |
| US-20260137368-A1 | ULTRASOUND NAVIGATION SYSTEM WITH SIMPLIFIED PROBE POSITIONING INSTRUCTIONS | ZYX, SON, FZD7 | ADRA2A 3030/4885ADRA2B 3014/4885ADRA2C 2781/4885 |
| US-12606868-B2 | Molecular biomarkers and targets for Fuchs' endothelial corneal dystrophy and glaucoma | COL2A1, SOD3, NOTCH3 | ADRA2A 2612/4885ADRA2B 2780/4885ADRA2C 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.